Physician profile
Yuri Simonian
NPI 1689831299
$5,794.59
in general payments reported to CMS, 2019-2025
31 companies · $572 in 2025
The $572 reported for 2025 was more than what 83% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $92.61 · 2021: $226 · 2022: $277 · 2023: $173 · 2024: $4,279 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,418 · Education: $1,500 · Food and Beverage: $757 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,417.62 |
| Education | $1,500.00 |
| Food and Beverage | $756.96 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,185.77 | 2022-2024 | |
| Meditrina | $361.05 | 2025 | |
| Abbvie INC. | $268.11 | 2019-2023 | Lo Loestrin Fe |
| Boston Scientific Corporation | $136.57 | 2024 | Solyx Sis System |
| Organon LLC | $105.74 | 2021-2025 | Nexplanon |
| Baxter Healthcare | $88.56 | 2022 | |
| Myriad Women'S Health, INC. | $79.52 | 2023 | Myrisk |
| Pfizer INC. | $56.39 | 2023-2024 | |
| Aspira Women'S Health INC | $54.57 | 2021 | |
| Merck Sharp & Dohme LLC | $46.95 | 2019-2021 | |
| Convatec INC. | $39.12 | 2021-2023 | |
| Ethicon US, LLC | $33.85 | 2025 | Stratafix |
| Roche Diagnostics Corporation | $30.89 | 2019 | |
| American Regent | $27.74 | 2025 | Injectafer |
| Avanos Medical | $24.81 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.81 | 2025 | Myosure Tissue Removal Device |
| Caldera Medical, INC | $21.22 | 2025 | |
| Sumitomo Pharma America, INC. | $20.38 | 2025 | Gemtesa |
| Millicent US INC | $18.50 | 2025 | Femlyv, Intrarosa |
| Evofem Biosciences, INC. | $17.74 | 2025 | Solosec, Phexx, Phexxi |
| Kci USA, INC. | $16.94 | 2019 | |
| Smith+Nephew, INC. | $16.78 | 2025 | Pico 14 |
| Mylan Pharmaceuticals INC. | $15.35 | 2021 | |
| Therapeuticsmd, INC. | $14.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.71 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.50 | 2025 | |
| Urovant Sciences INC | $14.39 | 2022 | |
| Renovia INC | $11.61 | 2021 | |
| Coopersurgical, INC. | $11.50 | 2021 | |
| Lupin INC. | $11.43 | 2020 | |
| Agile Therapeutics, INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuri Simonian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.